George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.
Exploring Daratumumab in Smoldering Multiple Myeloma
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
2
FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns
3
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
4
Phase 3 TRIDENT Trial Misses Survival End Point in Glioblastoma
5